论文部分内容阅读
目的探讨质子泵抑制剂在武汉地区的利用情况与发展趋势。方法对武汉地区34家入网医院2012—2014年质子泵抑制剂的销售金额、用药频度和限定日费用等进行排序分析。结果 3年来武汉地区医院质子泵抑制剂品种固定,销售金额持续上涨,其中兰索拉唑、奥美拉唑和泮托拉唑注射剂销售金额连续3年稳居前三。泮托拉唑用药频度最高,新型质子泵抑制剂艾司奥美拉唑和艾普拉唑销售金额增长迅速。结论武汉地区质子泵抑制剂应用基本合理,成熟的质子泵抑制剂还占主导地位,新型质子泵抑制剂具有较好的发展潜力,未来质子泵抑制剂市场格局可能改变。
Objective To explore the utilization and development trend of proton pump inhibitors in Wuhan. Methods The amount of sales of proton pump inhibitors, the frequency of medication and the limit day cost of 34 hospitalized hospitals in Wuhan from 2012 to 2014 were analyzed. Results In the past three years, the number of proton pump inhibitors in hospitals in Wuhan was fixed and the sales volume continued to rise. The sales amount of lansoprazole, omeprazole and pantoprazole remained the top three for three consecutive years. The pantoprazole medication frequency of the highest, the new proton pump inhibitors esomeprazole and ilaprazole sales increased rapidly. Conclusion The application of proton pump inhibitors in Wuhan is basically rational and mature proton pump inhibitors are still dominant. The new proton pump inhibitors have good development potential, and the market structure of proton pump inhibitors may change in the future.